TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg
Brief Summary: Because Diabetes Mellitus is one of the major risk factors for CV disease and lots of related evidences have been published including CARDS study that showed definite benefit of statin treatment in DM patients and influenced ADA guideline. \& NCEP ATP III update. However, there are large unmet medical needs for DM patients who don't reach their target LDL-C level defined NCEPT ATP III update because of physicians usually start with the lowest dose of statin and then titrate to the goal. Thus, we are curious about changing our prescription pattern into more tailored way; selecting starting dose based on the individual risk factors and concomitant status will impact the goal achieving rate for DM patients. Besides that, we are going to find out preliminary data about other markers change; small dense LDL and adiponectine;. Small dense LDL-C is more inflammatory and atherogenic LDL-C that may explain the impact of triglyceride. Adiponectin is another good marker related with obesity and metabolic syndrome.


Options:
A: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin
B: Intervention Type: DRUG; Name: Atorvastatin, 10mg, 20mg, 40mg; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Blood samples; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: atorvastatin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: Lovaza arm; Type: EXPERIMENTAL; Interventions: Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin | Intervention Type: DRUG; Name: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin; Assigned to Arm(s): Lovaza arm | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes
Brief Summary: Despite several clinical trials have clearly demonstrated that the correction of a single cardiovascular risk factor in patients with type 2 diabetes decreases the incidence of myocardial infarction and other cardiovascular disease (CVD) events, only the Steno study has been evaluating the effect of a multifactorial intervention strategy on macrovascular complications of diabetes. For this reason, the disease management approach currently endorsed by international guidelines (i.e correction of all major CVD risk factors to target levels usually lower than lower risk populations) has not been extensively investigated in terms of prevalence of application in current clinical practice and in terms of real efficacy.

The Multifactorial INtervention in type 2 Diabetes - ITaly (MIND.IT) is a multicentric two-phase study involving 9 Diabetes Care Units throughout Italy with the overall aims of: (1) investigating the degree of application of the international guidelines for CVD prevention in type 2 diabetic patients and (2) verifying whether the application of an intensive multi-factorial intervention inspired by these guidelines is feasible and effective in decreasing the incidence of new CVD events.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Arm Label: Intensive Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Intervention Type: OTHER; Name: Intensive care; Assigned to Arm(s): Intensive Care, Usual Care
B: Arm Label: Early SimCare Diabetes Group; Type: EXPERIMENTAL; Interventions: Other: Early SimCare Diabetes Group | Arm Label: Delayed SimCare Diabetes Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Delayed SimCare Diabetes Group | Intervention Type: OTHER; Name: Early SimCare Diabetes Group; Assigned to Arm(s): Early SimCare Diabetes Group | Intervention Type: OTHER; Name: Delayed SimCare Diabetes Group; Assigned to Arm(s): Delayed SimCare Diabetes Group
C: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Online disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Online disease management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Online disease management; Assigned to Arm(s): Online disease management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intravenous GLutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomized, Placebo-controlled Clinical Trial
Brief Summary: The purpose of this trial is to investigate if pharmacologically safe dose intravenous glutamine dipeptide supplementation to multiple trauma patients receiving enteral nutrition is associated with improved clinical outcomes in terms of decreased organ dysfunction, infectious complications, and other secondary outcomes


Options:
A: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Total Parenteral Nutrition with Glutamine | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Total Parenteral Nutrition without glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Total Parenteral Nutrition with Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Total Parenteral Nutrition without glutamine; Assigned to Arm(s): Control
B: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Other: Glutamine | Arm Label: Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Antioxidants | Arm Label: Glutamine + Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Glutamine + Antioxidants | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Antioxidants; Assigned to Arm(s): Antioxidants | Intervention Type: OTHER; Name: Glutamine + Antioxidants; Assigned to Arm(s): Glutamine + Antioxidants | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: alanyl-glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dipeptiven | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: normal saline | Intervention Type: DIETARY_SUPPLEMENT; Name: Dipeptiven; Assigned to Arm(s): alanyl-glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: normal saline; Assigned to Arm(s): normal saline
D: Arm Label: Enteral Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enteral Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Enteral Glutamine; Assigned to Arm(s): Enteral Glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.
Brief Summary: Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications).


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: insulin; Assigned to Arm(s): insulin
B: Arm Label: metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): insulin
C: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
D: Arm Label: Glyburide (Glyburide vs Insulin); Type: N/A; Interventions: Drug: Glyburide vs Insulin trials | Arm Label: Insulin (Glyburide vs Insulin); Type: N/A; Interventions: Drug: Glyburide vs Insulin trials | Arm Label: Metformin (Metformin vs Insulin); Type: N/A; Interventions: Drug: Metformin vs Insulin trials | Arm Label: Insulin (Metformin vs Insulin); Type: N/A; Interventions: Drug: Metformin vs Insulin trials | Arm Label: Metformin (Metformin vs Glyburide); Type: N/A; Interventions: Drug: Metformin vs Glyburide trials | Arm Label: Glyburide (Metformin vs Glyburide); Type: N/A; Interventions: Drug: Metformin vs Glyburide trials | Intervention Type: DRUG; Name: Glyburide vs Insulin trials; Assigned to Arm(s): Glyburide (Glyburide vs Insulin), Insulin (Glyburide vs Insulin) | Intervention Type: DRUG; Name: Metformin vs Insulin trials; Assigned to Arm(s): Insulin (Metformin vs Insulin), Metformin (Metformin vs Insulin) | Intervention Type: DRUG; Name: Metformin vs Glyburide trials; Assigned to Arm(s): Glyburide (Metformin vs Glyburide), Metformin (Metformin vs Glyburide)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.
Brief Summary: The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.

By improving disease knowledge, awareness of significant clinical deterioration and self-management skills for patients, this Home-Based COPD Management Program is expected to reduce the severity of exacerbations, the need for emergency hospitalisations, thus demonstrating the efficacy and the cost effectiveness of this intervention.


Options:
A: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Active implementation of a guideline for chronic disease | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: External control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active implementation of a guideline for chronic disease; Assigned to Arm(s): Intervention
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention 1; Type: OTHER; Interventions: Other: Intervention 1 | Arm Label: Intervention 2; Type: OTHER; Interventions: Other: Intervention 2 | Intervention Type: OTHER; Name: Intervention 1; Assigned to Arm(s): Intervention 1 | Intervention Type: OTHER; Name: Intervention 2; Assigned to Arm(s): Intervention 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.
Brief Summary: The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.

By improving disease knowledge, awareness of significant clinical deterioration and self-management skills for patients, this Home-Based COPD Management Program is expected to reduce the severity of exacerbations, the need for emergency hospitalisations, thus demonstrating the efficacy and the cost effectiveness of this intervention.


Options:
A: Arm Label: COPD education + Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: COPD education + Usual care | Arm Label: Physical activity self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity self-management | Intervention Type: BEHAVIORAL; Name: Physical activity self-management; Assigned to Arm(s): Physical activity self-management | Intervention Type: OTHER; Name: COPD education + Usual care; Assigned to Arm(s): COPD education + Usual care
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group psychoeducation | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group psychoeducation; Assigned to Arm(s): Intervention Group
C: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
D: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.
Brief Summary: The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.

By improving disease knowledge, awareness of significant clinical deterioration and self-management skills for patients, this Home-Based COPD Management Program is expected to reduce the severity of exacerbations, the need for emergency hospitalisations, thus demonstrating the efficacy and the cost effectiveness of this intervention.


Options:
A: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
C: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised COPD Rehabilitation (control group) | Arm Label: Online COPD rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Online COPD rehabilitation (experimental) | Intervention Type: BEHAVIORAL; Name: Supervised COPD Rehabilitation (control group); Assigned to Arm(s): Control group | Intervention Type: BEHAVIORAL; Name: Online COPD rehabilitation (experimental); Assigned to Arm(s): Online COPD rehabilitation
D: Arm Label: Pulmonary Telerehabilitation Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Telerehabilitation | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Telerehabilitation; Assigned to Arm(s): Pulmonary Telerehabilitation Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.
Brief Summary: The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.

By improving disease knowledge, awareness of significant clinical deterioration and self-management skills for patients, this Home-Based COPD Management Program is expected to reduce the severity of exacerbations, the need for emergency hospitalisations, thus demonstrating the efficacy and the cost effectiveness of this intervention.


Options:
A: Arm Label: usual care; Type: OTHER; Interventions: Behavioral: usual care | Arm Label: cooperation; Type: EXPERIMENTAL; Interventions: Behavioral: closer collaboration between hospital and primary healthcare system | Intervention Type: BEHAVIORAL; Name: closer collaboration between hospital and primary healthcare system; Assigned to Arm(s): cooperation | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): usual care
B: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
C: Arm Label: COPD, Telehealth; Type: EXPERIMENTAL; Interventions: Device: Telehealth | Arm Label: COPD, Normal clinical practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehealth; Assigned to Arm(s): COPD, Telehealth
D: Arm Label: Remote-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with remote-monitoring | Arm Label: Self-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with self-monitoring | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cloud Dx Kit with self-monitoring; Assigned to Arm(s): Self-Monitoring Program | Intervention Type: DEVICE; Name: Cloud Dx Kit with remote-monitoring; Assigned to Arm(s): Remote-Monitoring Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.
Brief Summary: The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.

By improving disease knowledge, awareness of significant clinical deterioration and self-management skills for patients, this Home-Based COPD Management Program is expected to reduce the severity of exacerbations, the need for emergency hospitalisations, thus demonstrating the efficacy and the cost effectiveness of this intervention.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
B: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
D: Arm Label: Case Management and Self-Management Education; Type: EXPERIMENTAL; Interventions: Other: Case Management and Self-Management Education | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Case Management and Self-Management Education | Intervention Type: OTHER; Name: Case Management and Self-Management Education; Assigned to Arm(s): Case Management and Self-Management Education, Usual Care

Answer: B